Does Protease-Antiprotease Imbalance Explain Chronic Obstructive Pulmonary Disease?

Area of Science:

• Pulmonary Medicine
• Genetics
• Molecular Biology

Background:

• Chronic obstructive pulmonary disease (COPD) is characterized by irreversible airflow limitation, often progressive and linked to inhaled toxins like cigarette smoke.
• The protease-antiprotease hypothesis posits that COPD and emphysema arise from an imbalance between matrix-degrading enzymes and their inhibitors in the lung.

Purpose of the Study:

• To review genetic evidence supporting the protease-antiprotease imbalance in COPD pathogenesis.
• To discuss the limitations of solely suppressing protease activity in alpha-1 antitrypsin deficiency (AATD).
• To propose alternative therapeutic strategies for AATD.

Main Methods:

• Review of existing genetic studies on COPD and protease-antiprotease interactions.
• Analysis of the molecular mechanisms underlying AATD.
• Evaluation of potential therapeutic targets beyond protease inhibition.

Main Results:

• Genetic data provide strong support for the role of protease-antiprotease imbalance in COPD development.
• In AATD, inhibiting protease activity alone may not halt disease progression due to underlying protein misfolding and polymerization.
• Emerging strategies like small molecules, RNA silencing, and targeting protein misfolding show promise for AATD treatment.

Conclusions:

• The protease-antiprotease imbalance is a key factor in COPD pathogenesis, supported by genetic evidence.
• Therapeutic approaches for AATD should address the root cause of protein misfolding and polymerization, not just protease activity.
• Novel treatments targeting molecular pathways offer a more effective strategy for managing AATD and potentially COPD.